Displaying drugs 1676 - 1700 of 2339 in total
Nafamostat
Nafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties. It has been used in trials studying the prevention of Liver Transplantation and Postreperfusion Syndrome. The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing...
Investigational
Daphnetin
Daphnetin is under investigation in clinical trial NCT06329167 (Daphnetin Capsules for Lower Limb Lymphoedema Following Gynaecological Surgery).
Investigational
REP8839
REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
Investigational
Devimistat
Devimistat (CPI-613) has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Advanced Cancer, and Pancreatic Cancer, among others.
Investigational
Omburtamab I-131
Investigational
Granaticin B
Investigational
AZD8529
AZD8529 is under investigation in clinical trial NCT00921804 (Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients).
Investigational
APC8020
Investigational
Viral Macrophage-Inflammatory Protein
Viral macrophage inflammatory protein-II (vMIP) is a highly basic protein and human chemokine analog encoded by human herpesvirus-8. The structure of vMIP consists of 71 residues and is a monomer under most conditions. It helps its virus evade the host immune system through selectively blocking and activating different receptors, preferentially...
Investigational
Matched Description: … protein-II (vMIP) is a highly basic protein and human chemokine analog encoded by human herpesvirus-8. …
N,N,N-Trimethyl-2-(phosphonooxy)ethanaminium
Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
Experimental
RDEA806
RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.
Investigational
SPL84-23-1
SPL84-23-1 is a sodium salt of 19-bp single-stranded RNA uniformly modified 2'-O-(2-methoxyethyl) phosphorothioate Antisense Oligonucleotide (ASO) consisting of 19 nucleotide residues with the sequence 5'-5MeC-5MeU-G-5MeC-A-A-5MeC-A-G-A-5MeU-G-G-A-A-G-A-5MeC-5MeU-3'
Investigational
Sulisobenzone
Sulisobenzone is approved by the FDA in concentrations of up to 10% and in Canada, is approved by Health Canada at the same concentrations . It works to filter out both UVA and UVB rays, protecting the skin from sun UV damage .
The UV-filter substance, sulisobenzone (BP-4) is widely...
Experimental
Matched Mixtures name: … Sebamed Sun Cream SPF 8 ... Sebamed Sun Lotion SPF 8 …
Urolithin A
Urolithin A is a metabolite of ellagic acid. It has been demonstrated to stimulate mitophagy and improve muscle health in old animals and in preclinical models of aging.
Investigational
BBV152
BBV152 is a vaccine candidate created by the Indian Council of Medical Research (ICMR). The candidate, a whole virion inactivated SARS-CoV-2 vaccine, was developed from a well-known SARS-CoV-2 strain and a vero cell platform (CCL-81) with adjuncts of either aluminum hydroxide gel (Algel) or a novel TLR7/8 agonist adsorbed gel....
Investigational
Matched Description: … vero cell platform (CCL-81) with adjuncts of either aluminum hydroxide gel (Algel) or a novel TLR7/8 ... The formulation with the TLR7/8 adjuvant specifically induced significant Th1 biased antibody responses …
RU83876
Experimental
RU82209
Experimental
RU85053
Experimental
Basic Fibroblast Growth Factor
Basic Fibroblast Growth Factor (bFGF) is a single-chain polypeptide growth factor that plays a significant role in the process of wound healing and is a potent inducer of physiologic angiogenesis. Several different forms of the human protein exist ranging from 18-24 kDa in size due to the use of alternative...
Investigational
Matched Description: … It has a 55 percent amino acid residue identity to Fibroblast Growth Factor 1 and has potent heparin-binding …
R048-8071
Experimental
PLX8394
PLX8394 is under investigation in clinical trial NCT02428712 (A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors).
Investigational
Tetrahydrofolic acid
Tetrahydrofolic acid is a folic acid derivative that is produced from dihydrofolic acid after conversion by dihydrofolate reductase. It is converted into 5,10-methylenetetrahydrofolate by serine hydroxymethyltransferase. It is a soluble coenzyme in many reactions, especially in the metabolism of amino acids and nucleic acids.
Nutraceutical
Displaying drugs 1676 - 1700 of 2339 in total